团队的一项临床研究“Safety and efficacy of sofosbuvir-based treatment of acute hepatitis C in end-stage renal disease patients undergoing haemodialysis”发表在Aliment Pharmacol Ther，该杂志的影响因子为7.9；何英利教授是该论著的第一作者。（He, Y. L., et al. (2018). "Safety and efficacy of sofosbuvir-based treatment of acute hepatitis C in end-stage renal disease patients undergoing haemodialysis." Aliment Pharmacol Ther 47(4): 526-532.）

https://onlinelibrary.wiley.com/doi/abs/10.1111/apt.14429